Strahlentherapie bei Patientinnen mit oligometastasiertem Mammakarzinom

Translated title of the contribution: Radiotherapy in patients with oligometastatic breast cancer

David Krug*, Alexander Fabian, Florian Pyschny, Oliver Blanck, Kathrin Dellas, Nicolai Maass, Jürgen Dunst

*Corresponding author for this work
2 Citations (Scopus)


Background: New developments in the systemic treatment of patients with metastatic breast cancer have led to enormous improvements, rendering a survival time of several years achievable for many patients. New insights in tumor biology and observation of clinical cases have led to the definition of oligometastases as a distinct disease stage. Objectives: To analyse the potential role of stereotactic radiotherapy in the treatment of patients with oligometastatic breast cancer. Methods: Semi-structured literature review. Results: Stereotactic radiotherapy is a highly effective and safe local treatment option for patients with brain, lung, liver and bone metastases. A randomized clinical phase II-trial (SABR-COMET) enrolling patients with oligometastases from various primary tumors showed an improvement in overall survival from stereotactic radiotherapy. Preclinical and limited clinical data suggest immune-activating effects of stereotactic radiotherapy. Discussion: Further clinical trials enrolling patients with specific tumor types are needed. The OLIGOMA-trial will further analyze the role of stereotactic radiotherapy in addition to standard systemic therapy in patients with breast cancer and up to 5 metastatic sites.

Translated title of the contributionRadiotherapy in patients with oligometastatic breast cancer
Original languageGerman
Issue number12
Pages (from-to)918-926
Number of pages9
Publication statusPublished - 01.12.2019


Dive into the research topics of 'Radiotherapy in patients with oligometastatic breast cancer'. Together they form a unique fingerprint.

Cite this